Cabaletta Bio Shares Are Trading Lower. The Company Announced Initial Clinical Data From Each of the First Two Patients Dosed With CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE Trials.
Cabaletta Bio Shares Are Trading Lower. The Company Announced Initial Clinical Data From Each of the First Two Patients Dosed With CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE Trials.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.